description of group X is clarified. Further, the recitation of a pharmaceutical carrier is deleted from claim 11 and now recited in dependent claim 44. Claim 16 is amended to include proviso clauses similar to those recited in claim 11. Also, the description of Group X is clarified.

Claim 48 is similar to claim 11 but defines the patient as having renal insufficiency. See, e.g., page 3, lines 3-7. Claim 49 recites a generic NMR imaging method claim in Jepson format.

Rejection under 35 U.S.C. §112, second paragraph

The language of claim 11 is clarified above to clearly indicate that one of the substituents Z^1 and Z^2 is H while the other is a structure of the formula $-(CH_2)_m-(C_6H_4)_1-(O)_k-(CH_2)_n-(C_6H_4)_1-(O)_r-R$. Thus, the phrase "one of the substituents Z^1 and Z^2 is hydrogen and the other is not hydrogen" has been deleted. Claim 16 is amended in a similar manner.

The rejection's reference to unclear "Markush" language is not understood. Markush language is used to define a variable as being selected from a group of possibilities. It is acceptable to use either "and" or "or" in reciting the Markush groups. See M.P.E.P. §2173.05(h)(a), page 2100-153.

In any event, the recitation "at least one of q and 1 is 1" is not Markush language. In this phrase, neither q nor 1 is defined as selected from a group of possibilities. Instead, this language recites that at least one of q and 1 is a single possibility, i.e., 1. This language is not unclear to one of ordinary skill in the art merely because the variables q and 1 are listed using the conjunction "and."

In view of the above remarks, it is respectfully submitted that the language of applicants' claims is sufficiently definite to one of ordinary skill in the art. Withdrawal of the rejection under 35 U.S.C. §112, second paragraph, is respectfully requested.

Rejections of Claim 16 under 35 U.S.C. §102(e)

Deutsch et al. (U.S. '700) and Berg et al. (U.S. '208) fail to anticipate applicants' claim 16. Neither Deutsch et al. nor Berg et al. disclose or suggest a compound exhibiting side group substituents in accordance with applicants' groups Z¹ and Z². Withdrawal of the rejections under 35 U.S.C. §102(e) is respectfully requested.



Rejection under 35 U.S.C. §103(a)

This rejection is rendered moot by the cancellation of claims 41-43. Cancellation of claims 41-43 is not to be construed as an acquiescence to this or any other ground of rejection.

In view of the above remarks, allowance of the instant application is respectfully requested.

Respectfully submitted,

Brion P. Heaney (Reg. No. 32,542)

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I

2200 Clarendon Boulevard, Suite 1400

Arlington, Virginia 22201

(703) 812-5308

Internet Address: heaney@mwzb.com

Filed: March 19, 1997

BPH:kdp147:sch1412.am2